Rigel Appoints Veteran Pharma Executive Michael Miller To Board Of Directors

Rigel Pharmaceuticals has appointed biotechnology industry veteran Michael P. Miller to its Board of Directors. Miller brings more than 40 years of experience across senior commercial and leadership roles in the pharmaceutical sector.

He currently serves on the boards of Puma Biotechnology and BioXcel Therapeutics and previously held the position of Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals until his retirement in 2020. Earlier in his career, Miller was Senior Vice President and Chief Commercial Officer at Vivus, and led Genentech’s HER Family Oncology franchise as Vice President.

"Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines and evaluating potential in-licensing opportunities – areas where Mike has extensive experience."

His background also includes senior commercial leadership roles at Connetics Corporation, later acquired by GSK’s Stiefel Laboratories, and at ALZA Corporation, which was acquired by Johnson & Johnson, as well as various sales and marketing positions at Syntex Corporation.

"Over the years I have seen Rigel evolve into a profitable company with a strong commercial engine that can fund a promising development pipeline, which is a privileged position in biotechnology space," said Mr. Miller. "I am thrilled to join Rigel as a Director and contribute to the critical work focused on realizing opportunities to serve more patients with hematologic disorders and cancer."

Miller holds a Bachelor’s degree in Business Administration and Finance from the University of San Francisco and an MBA in Information and Computer Systems from San Francisco State University.